PORT-77

Phase 1Small molecule

PPortal Therapeutics, Inc.

PORT-77 is one of 7 small molecule programs targeting Double-blind. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Double-BlindRecruiting

Double-BlindPhase 1

Recruiting

Competition

Competitive Landscape

10 competitors in Double-Blind

#DrugCompanyPhaseTrials

Olumiant

Eli Lilly

Phase 3

1 2

Albenza

IImpax Laboratories, LLC

Phase 3

1 3

Everolimus and Lonafarnib

BBoston Children's Hospital

Phase 3

1 4

Inosine Pranobex

NNewport Pharmaceuticals International

Preclinical

2 5

PORT-77

PPortal Therapeutics, Inc.

Phase 1

1 6

Western Therapy

JJiangxi Qingfeng Pharmaceutical Co. Ltd.

Preclinical

1 7

Interferon Alfa-N3

IInterferon Sciences

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

PreclinicalRecruiting

Erythropoietic Protoporphyria (EPP)

NCT07820085

Clinical

Trials by Indication[1]

Erythropoietic Protoporphyria (EPP)2 trials

A Phase 2b/3, Quadruple-Blinded, Randomized, Placebo-Controlled Study of PORT-77 Administered Orally to Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria and an Open-Label Extension

Recruiting·PPortal Therapeutics, Inc.·Preclinical·NCT07820085·225 enrolled

A Phase 2a, Blinded, Randomized, Placebo-Controlled Study of PORT-77 Administered Orally to Adults With Erythropoietic Protoporphyria

Completed·PPortal Therapeutics, Inc.·Phase 2·NCT06971900·28 enrolled

Double-blind1 trial

Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants

Recruiting·PPortal Therapeutics, Inc.·Phase 1·NCT06346509·108 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PORT-77. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PORT-77 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PORT-77. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Portal Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PPortal Therapeutics, Inc.

PORT-77

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Erythropoietic Protoporphyria (EPP)2 trials

Double-blind1 trial

References

Drug Info

Quick Facts

Related News